Towards Identifying Protective B-Cell Epitopes: The PspA Story

Frontiers in Microbiology
Naeem Khan, Arif T Jan

Abstract

Pneumococcal surface protein A (PspA) is one of the most abundant cell surface protein of Streptococcus pneumoniae (S. pneumoniae). PspA variants are structurally and serologically diverse and help evade complement-mediated phagocytosis of S. pneumoniae, which is essential for its survival in the host. PspA is currently been screened for employment in the generation of more effective (serotype independent) vaccine to overcome the limitations of polysaccharide based vaccines, providing serotype specific immune responses. The cross-protection eliciting regions of PspA localize to the α-helical and proline rich regions. Recent data indicate significant variation in the ability of antibodies induced against the recombinant PspA variants to recognize distinct S. pneumoniae strains. Hence, screening for the identification of the topographical repertoire of B-cell epitopes that elicit cross-protective immune response seems essential in the engineering of a superior PspA-based vaccine. Herein, we revisit epitope identification in PspA and the utility of hybridoma technology in directing the identification of protective epitope regions of PspA that can be used in vaccine research.

References

Oct 25, 1975·Journal of Molecular Biology·A D McLachlan, M Stewart
Jul 1, 1989·Clinical Microbiology Reviews·V A Fischetti
Sep 1, 1969·The Journal of Experimental Medicine·P L MassonE Schonne
May 1, 1994·Journal of Bacteriology·J Yother, J M White
Mar 20, 1999·Biochemical and Biophysical Research Communications·B L TrigattiG E Gerber
Jan 6, 2000·Archives of Biochemistry and Biophysics·M J JedrzejasE Lamani
Sep 19, 2000·Infection and Immunity·S K HollingsheadD E Briles
Apr 9, 2001·Infection and Immunity·A HåkanssonD E Briles
Jun 20, 2001·The Journal of Biological Chemistry·M J JedrzejasR S Becker
Dec 13, 2002·Proceedings of the National Academy of Sciences of the United States of America·Jeremy S BrownMarina Botto
Sep 17, 2005·Pharmacotherapy·Angela E Bridy-PappasDaniel J Isaacman
Nov 2, 2005·Cellular and Molecular Life Sciences : CMLS·P P WardO M Conneely
Jan 26, 2006·Journal of Medical Microbiology·Susan K HollingsheadUNKNOWN Pneumococcal Proteins Epi Study Group
Mar 15, 2006·Journal of Medical Microbiology·Daniela M FerreiraLuciana C C Leite
May 4, 2006·The Journal of Immunology : Official Journal of the American Association of Immunologists·Jose YusteJeremy S Brown
Feb 28, 2007·Vaccine·Michèle Anne BarocchiRino Rappuoli
Feb 22, 2008·Journal of Medical Microbiology·Michelle DarrieuxEliane N Miyaji
Aug 30, 2008·Clinical and Vaccine Immunology : CVI·Merit M MelinHelena M Käyhty
Apr 22, 2009·The Journal of Immunology : Official Journal of the American Association of Immunologists·Soma RohatgiDevinder Sehgal
Oct 30, 2009·Expert Review of Vaccines·Roman Prymula, Lode Schuerman
May 4, 2010·Pediatrics·Kristina A BryantUNKNOWN PCV13 Infant Study Group
Jul 8, 2011·Clinical Microbiology Reviews·Barry B Mook-KanamoriDiederik van de Beek

❮ Previous
Next ❯

Citations

Jun 22, 2018·Journal of Medical Microbiology·Mitsuyo KawaguchiyaNobumichi Kobayashi
Jan 25, 2019·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Mitsuyo KawaguchiyaNobumichi Kobayashi
Oct 19, 2019·Vaccines·Victor MoraisNorma Suarez
Jan 7, 2020·Expert Review of Vaccines·T R ConversoL C C Leite
Mar 31, 2018·Frontiers in Immunology·Danielle A Wagner-MuñizBalaji Narasimhan

❮ Previous
Next ❯

Methods Mentioned

BETA
circular dichroism
PpsA

Related Concepts

Related Feeds

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.